DOCSLIB.ORG

Specialty Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Specialty Drug List Blue Cross Blue Shield of North Dakota Specialty Drug List Specialty Drug – medications or drugs that are generally high cost and may have other considerations such as special drug administration, limited availability, unique delivery and dispensing or unique and/or required patient support or monitoring. Use of some products may be approved only after certain criteria are met. Refer to Restricted-Use Drug lists for other applicable criteria. DRUG NAME(S) GENERIC NAME ABIRATERONE ACETATE ABIRATERONE ACETATE TAB 250 MG, ABIRATERONE ACETATE TAB 500 MG ACTEMRA TOCILIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 162 MG/0.9ML ACTEMRA ACTPEN TOCILIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR 162 MG/0.9ML ACTHAR CORTICOTROPIN INJ GEL 80 UNIT/ML ACTIMMUNE INTERFERON GAMMA-1B INJ 100 MCG/0.5ML (2000000 UNIT/0.5ML) ADCIRCA TADALAFIL TAB 20 MG (PAH) RIOCIGUAT TAB 0.5 MG, RIOCIGUAT TAB 1 MG, RIOCIGUAT TAB 1.5 MG, RIOCIGUAT TAB 2 MG, RIOCIGUAT ADEMPAS TAB 2.5 MG AFINITOR EVEROLIMUS TAB 10 MG, EVEROLIMUS TAB 2.5 MG, EVEROLIMUS TAB 5 MG, EVEROLIMUS TAB 7.5 MG EVEROLIMUS TAB FOR ORAL SUSP 2 MG, EVEROLIMUS TAB FOR ORAL SUSP 3 MG, EVEROLIMUS TAB FOR AFINITOR DISPERZ ORAL SUSP 5 MG ALECENSA ALECTINIB HCL CAP 150 MG (BASE EQUIVALENT) ALFERON N INTERFERON ALFA-N3 INJ 5000000 UNIT/ML ALKERAN MELPHALAN TAB 2 MG HYDROCORTISONE CAP SPRINKLE 0.5 MG, HYDROCORTISONE CAP SPRINKLE 1 MG, HYDROCORTISONE CAP ALKINDI SPRINKLE SPRINKLE 2 MG, HYDROCORTISONE CAP SPRINKLE 5 MG BRIGATINIB TAB 180 MG, BRIGATINIB TAB 30 MG, BRIGATINIB TAB 90 MG, BRIGATINIB TAB INITIATION ALUNBRIG THERAPY PACK 90 MG & 180 MG ALYQ TADALAFIL TAB 20 MG (PAH) AMBRISENTAN AMBRISENTAN TAB 10 MG, AMBRISENTAN TAB 5 MG AMPYRA DALFAMPRIDINE TAB ER 12HR 10 MG APOKYN APOMORPHINE HCL SOLN CARTRIDGE 30 MG/3ML DARBEPOETIN ALFA SOLN INJ 100 MCG/ML, DARBEPOETIN ALFA SOLN INJ 200 MCG/ML, DARBEPOETIN ALFA SOLN INJ 25 MCG/ML, DARBEPOETIN ALFA SOLN INJ 300 MCG/ML, DARBEPOETIN ALFA SOLN INJ 40 MCG/ML, DARBEPOETIN ALFA SOLN INJ 60 MCG/ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 10 MCG/0.4ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 100 MCG/0.5ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ARANESP ALBUMIN FREE 150 MCG/0.3ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 200 MCG/0.4ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 25 MCG/0.42ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 300 MCG/0.6ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 40 MCG/0.4ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 500 MCG/ML, DARBEPOETIN ALFA SOLN PREFILLED SYRINGE 60 MCG/0.3ML ARCALYST RILONACEPT FOR INJ 220 MG ARIKAYCE AMIKACIN SULFATE LIPOSOME INHAL SUSP 590 MG/8.4ML (BASE EQ) AUBAGIO TERIFLUNOMIDE TAB 14 MG, TERIFLUNOMIDE TAB 7 MG AUSTEDO DEUTETRABENAZINE TAB 12 MG, DEUTETRABENAZINE TAB 6 MG, DEUTETRABENAZINE TAB 9 MG AVONEX INTERFERON BETA-1A IM PREFILLED SYRINGE KIT 30 MCG/0.5ML AVONEX PEN INTERFERON BETA-1A IM AUTO-INJECTOR KIT 30 MCG/0.5ML AYVAKIT AVAPRITINIB TAB 100 MG, AVAPRITINIB TAB 200 MG, AVAPRITINIB TAB 300 MG BAFIERTAM MONOMETHYL FUMARATE CAPSULE DELAYED RELEASE 95 MG BALVERSA ERDAFITINIB TAB 3 MG, ERDAFITINIB TAB 4 MG, ERDAFITINIB TAB 5 MG BELIMUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML, BELIMUMAB SUBCUTANEOUS BENLYSTA SOLUTION PREFILLED SYRINGE 200 MG/ML BERINERT C1 ESTERASE INHIBITOR (HUMAN) FOR IV INJ KIT 500 UNIT BETASERON INTERFERON BETA-1B FOR INJ KIT 0.3 MG BETHKIS TOBRAMYCIN NEBU SOLN 300 MG/4ML BEXAROTENE BEXAROTENE CAP 75 MG BOSENTAN BOSENTAN TAB 125 MG, BOSENTAN TAB 62.5 MG BOSULIF BOSUTINIB TAB 100 MG, BOSUTINIB TAB 400 MG, BOSUTINIB TAB 500 MG BRAFTOVI ENCORAFENIB CAP 50 MG, ENCORAFENIB CAP 75 MG BRAVELLE UROFOLLITROPIN PURIFIED FOR INJ 75 UNIT BRONCHITOL MANNITOL INHAL CAP 40 MG Blue Cross Blue Shield of North Dakota Updated 9/1/2021 Page 1 of 12 An Independent Licensee of the Blue Cross and Blue Shield Association Information subject to change Blue Cross Blue Shield of North Dakota Specialty Drug List DRUG NAME(S) GENERIC NAME BRONCHITOL TOLERANCE MANNITOL INHAL CAP 40 MG TEST BRUKINSA ZANUBRUTINIB CAP 80 MG BUPHENYL SODIUM PHENYLBUTYRATE ORAL POWDER 3 GM/TEASPOONFUL, SODIUM PHENYLBUTYRATE TAB 500 MG BYNFEZIA PEN OCTREOTIDE ACETATE SOLN PEN-INJECTOR 2500 MCG/ML (2.8 ML) CABLIVI CAPLACIZUMAB-YHDP FOR INJ KIT 11 MG CABOZANTINIB S-MALATE TAB 20 MG (BASE EQUIVALENT), CABOZANTINIB S-MALATE TAB 40 MG (BASE CABOMETYX EQUIVALENT), CABOZANTINIB S-MALATE TAB 60 MG (BASE EQUIVALENT) CALQUENCE ACALABRUTINIB CAP 100 MG CAPECITABINE CAPECITABINE TAB 150 MG, CAPECITABINE TAB 500 MG CAPRELSA VANDETANIB TAB 100 MG, VANDETANIB TAB 300 MG CARBAGLU CARGLUMIC ACID TAB 200 MG CAYSTON AZTREONAM LYSINE FOR INHAL SOLN 75 MG (BASE EQUIVALENT) CERDELGA ELIGLUSTAT TARTRATE CAP 84 MG (BASE EQUIVALENT) CETROTIDE CETRORELIX ACETATE FOR INJ KIT 0.25 MG CHENODAL CHENODIOL TAB 250 MG CHOLBAM CHOLIC ACID CAP 250 MG, CHOLIC ACID CAP 50 MG CHORIONIC CHORIONIC GONADOTROPIN FOR IM INJ 10000 UNIT GONADOTROPIN CIMZIA CERTOLIZUMAB PEGOL FOR INJ KIT 2 X 200 MG, CERTOLIZUMAB PEGOL INJ KIT 2 X 200 MG/ML CIMZIA STARTER KIT CERTOLIZUMAB PEGOL INJ KIT 6 X 200 MG/ML CINACALCET CINACALCET HCL TAB 30 MG (BASE EQUIV), CINACALCET HCL TAB 60 MG (BASE EQUIV), CINACALCET HCL TAB HYDROCHLORIDE 90 MG (BASE EQUIV) CLOVIQUE TRIENTINE HCL CAP 250 MG CABOZANTINIB S-MAL CAP 1 X 80 MG & 1 X 20 MG (100 DOSE) KIT, CABOZANTINIB S-MAL CAP 1 X 80 MG & 3 COMETRIQ X 20 MG (140 DOSE) KIT, CABOZANTINIB S-MALATE CAP 3 X 20 MG (60 MG DOSE) KIT GLATIRAMER ACETATE SOLN PREFILLED SYRINGE 20 MG/ML, GLATIRAMER ACETATE SOLN PREFILLED COPAXONE SYRINGE 40 MG/ML COPIKTRA DUVELISIB CAP 15 MG, DUVELISIB CAP 25 MG SECUKINUMAB SUBCUTANEOUS PREF SYR 150 MG/ML (300 MG DOSE), SECUKINUMAB SUBCUTANEOUS COSENTYX SOLN PREFILLED SYRINGE 150 MG/ML, SECUKINUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 75 MG/0.5ML COSENTYX SENSOREADY SECUKINUMAB SUBCUTANEOUS AUTO-INJ 150 MG/ML (300 MG DOSE), SECUKINUMAB SUBCUTANEOUS PEN SOLN AUTO-INJECTOR 150 MG/ML COTELLIC COBIMETINIB FUMARATE TAB 20 MG (BASE EQUIVALENT) CRYSVITA BUROSUMAB-TWZA INJ 10 MG/ML, BUROSUMAB-TWZA INJ 20 MG/ML, BUROSUMAB-TWZA INJ 30 MG/ML CUPRIMINE PENICILLAMINE CAP 250 MG CYSTADROPS CYSTEAMINE HCL OPHTH SOLN 0.37% (BASE EQUIVALENT) CYSTAGON CYSTEAMINE BITARTRATE CAP 150 MG, CYSTEAMINE BITARTRATE CAP 50 MG CYSTARAN CYSTEAMINE HCL OPHTH SOLN 0.44% (BASE EQUIVALENT) DACLATASVIR DIHYDROCHLORIDE TAB 30 MG (BASE EQUIVALENT), DACLATASVIR DIHYDROCHLORIDE TAB 60 DAKLINZA MG (BASE EQUIVALENT) DALFAMPRIDINE ER DALFAMPRIDINE TAB ER 12HR 10 MG GLASDEGIB MALEATE TAB 100 MG (BASE EQUIVALENT), GLASDEGIB MALEATE TAB 25 MG (BASE DAURISMO EQUIVALENT) DEFERASIROX GRANULES PACKET 180 MG, DEFERASIROX GRANULES PACKET 360 MG, DEFERASIROX GRANULES PACKET 90 MG, DEFERASIROX TAB 180 MG, DEFERASIROX TAB 360 MG, DEFERASIROX TAB 90 MG, DEFERASIROX DEFERASIROX TAB FOR ORAL SUSP 125 MG, DEFERASIROX TAB FOR ORAL SUSP 250 MG, DEFERASIROX TAB FOR ORAL SUSP 500 MG DEFERIPRONE DEFERIPRONE TAB 500 MG DEPEN TITRATABS PENICILLAMINE TAB 250 MG STIRIPENTOL CAP 250 MG, STIRIPENTOL CAP 500 MG, STIRIPENTOL PACKET 250 MG, STIRIPENTOL PACKET DIACOMIT 500 MG DIMETHYL FUMARATE CAPSULE DELAYED RELEASE 120 MG, DIMETHYL FUMARATE CAPSULE DELAYED DIMETHYL FUMARATE RELEASE 240 MG Blue Cross Blue Shield of North Dakota Updated 9/1/2021 Page 2 of 12 An Independent Licensee of the Blue Cross and Blue Shield Association Information subject to change Blue Cross Blue Shield of North Dakota Specialty Drug List DRUG NAME(S) GENERIC NAME DIMETHYL FUMARATE DIMETHYL FUMARATE CAPSULE DR STARTER PACK 120 MG & 240 MG STARTERPACK DOJOLVI TRIHEPTANOIN ORAL LIQUID 100% DOPTELET AVATROMBOPAG MALEATE TAB 20 MG (BASE EQUIV) DROXIA HYDROXYUREA CAP 200 MG, HYDROXYUREA CAP 300 MG, HYDROXYUREA CAP 400 MG DROXIDOPA DROXIDOPA CAP 100 MG, DROXIDOPA CAP 200 MG, DROXIDOPA CAP 300 MG DUPILUMAB SUBCUTANEOUS SOLN PEN-INJECTOR 200 MG/1.14ML, DUPILUMAB SUBCUTANEOUS SOLN PEN- DUPIXENT INJECTOR 300 MG/2ML, DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 200 MG/1.14ML, DUPILUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE 300 MG/2ML EGRIFTA TESAMORELIN ACETATE FOR INJ 1 MG (BASE EQUIV) EGRIFTA SV TESAMORELIN ACETATE FOR INJ 2 MG (BASE EQUIV) LEUPROLIDE ACETATE (3 MONTH) FOR SUBCUTANEOUS INJ KIT 22.5MG, LEUPROLIDE ACETATE (4 MONTH) ELIGARD FOR SUBCUTANEOUS INJ KIT 30 MG, LEUPROLIDE ACETATE (6 MONTH) FOR SUBCUTANEOUS INJ KIT 45 MG, LEUPROLIDE ACETATE FOR SUBCUTANEOUS INJ KIT 7.5 MG DEFLAZACORT SUSP 22.75 MG/ML, DEFLAZACORT TAB 18 MG, DEFLAZACORT TAB 30 MG, DEFLAZACORT TAB EMFLAZA 36 MG, DEFLAZACORT TAB 6 MG EMPAVELI PEGCETACOPLAN SUBCUTANEOUS SOLN 1080 MG/20ML (54 MG/ML) ETANERCEPT FOR SUBCUTANEOUS INJ 25 MG, ETANERCEPT SUBCUTANEOUS INJ 25 MG/0.5ML, ETANERCEPT ENBREL SUBCUTANEOUS SOLN PREFILLED SYRINGE 25 MG/0.5ML, ETANERCEPT SUBCUTANEOUS SOLN PREFILLED SYRINGE 50 MG/ML ENBREL MINI ETANERCEPT SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML ENBREL SURECLICK ETANERCEPT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML ENDARI GLUTAMINE (SICKLE CELL) POWD PACK 5 GM ENSPRYNG SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE 120 MG/ML EPCLUSA SOFOSBUVIR-VELPATASVIR TAB 200-50 MG, SOFOSBUVIR-VELPATASVIR TAB 400-100 MG EPIDIOLEX CANNABIDIOL SOLN 100 MG/ML EPOETIN ALFA INJ 10000 UNIT/ML, EPOETIN ALFA INJ 2000 UNIT/ML, EPOETIN ALFA INJ 20000 UNIT/ML, EPOGEN EPOETIN ALFA INJ 3000 UNIT/ML, EPOETIN ALFA INJ 4000 UNIT/ML ERIVEDGE VISMODEGIB CAP 150 MG ERLEADA APALUTAMIDE TAB 60 MG ERLOTINIB HCL TAB 100 MG (BASE EQUIVALENT), ERLOTINIB HCL TAB 150 MG (BASE EQUIVALENT), ERLOTINIB HYDROCHLORIDE ERLOTINIB HCL TAB 25 MG (BASE EQUIVALENT) ESBRIET PIRFENIDONE CAP 267 MG, PIRFENIDONE TAB 267 MG, PIRFENIDONE TAB 801 MG ETOPOSIDE ETOPOSIDE CAP 50 MG EVENITY ROMOSOZUMAB-AQQG INJ SOLN PREFILLED
Load more

Recommended publications
  • September 11, 2018 DUR Minutes
    Maine Department of Health and Human Services PAUL R. LEPAGE MaineCare Services BETHANY L. HAMM GOVERNOR Pharmacy Unit ACTING COMMISSIONER 11 State House Station Augusta, Maine 04333-0011 TO: Maine Drug Utilization Review Board DATE: 9/14/2018 RE: Maine DUR Board Meeting minutes from September 11, 2018 ATTENDANCE PRESENT ABSENT EXCUSED Linda Glass, MD X Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, X Maine Medical CTR Mike Antoniello, MD X Kathleen Polonchek, MD X Kenneth McCall, PharmD X Steve Diaz, MD X Erin Ackley, PharmD. X Corinn Martineau, PharmD. X Non –Voting Mike Ouellette, R.Ph., Change Healthcare X Jeffery Barkin, MD, Change Healthcare X Christopher Pezzullo, State Health Officer DHHS, DO X Jill Kingsbury, MaineCare Pharmacy Director X Guests of the Board: Ed Bosshart, PharmD, Jeff Caulfield, Lead Epidemiologist for Viral Infections from CDC: Discussed HCV treatment. CALL TO ORDER: 5:30PM Jill Kingsbury called the meeting to order at 5:30 PM. PUBLIC COMMENTS Robert Mead from Pfizer: Highlighted the attributes of Retacrit. Jane Guo from Otsuka: Highlighted the attributes of Jynarque. OLD BUSINESS DUR MINUTES The June DUR meeting minutes were accepted as written. MAINECARE UPDATE No update at this time. NEW BUSINESS INTRODUCTION: USE OF CHRONIC TRIPTANS The use of triptans has become standard of care for the treatment of acute migraine headaches, given their effectiveness, safety and tolerability. However, like many medications used to treat migraine, overuse renders them less effective. Additionally, rebound headaches from triptan overuse is common. For patients who experience frequent headaches, or whose headaches are long lasting or chronic, use of headache prophylactic medications are recommended by several medical associations, including the American Headache Society and the American Academy of Neurology.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • TEXAS MEDICAID Clinical Edit Prior Authorization Epoetin Alfa (PROCRIT)
    TEXAS MEDICAID Clinical Edit Prior Authorization epoetin alfa (PROCRIT) STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name: Patient First & Last Name: Prescriber NPI: Patient Address: Prescriber Address: Patient ID: Prescriber Phone: Patient Date of Birth: Prescriber Fax: STEP 2: MEDICATION INFORMATION Medication Requested (Name): Quantity Requested: Dose Requested: Dosing Instructions: Patient’s Primary Diagnosis: ____________________________________ ICD 10 Code: __________ Please indicate ONE (1) of the following: OR STAR / STAR KIDS client (Go to Step 3 - PDL PA Criteria Applies) OR CHIP / PERINATE client (Go to Step 4) STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT 1. Has the client failed a 30-day treatment trial with at least 1 preferred agent in the last 180 days? Yes (Go to Step 4 Question 1) No (Go to #2) 2. Is there a documented allergy or contraindication to preferred agents in this class? Yes (Go to Step 4 Question 1) No (Go to #3) 3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? Yes (Go to Step 4 Question 1) No (Deny) Rev. 11/18/2020 Page 1 of 3 Version 1.5 STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA 1. Does the client have a diagnosis of chronic renal failure in the last 730 days? Yes (Go to #7) No (Go to #2) 2. Does the client have a diagnosis of cancer in the last 730 days? Yes (Go to #3) No (Go to #5) 3. Does the client have a history of an antineoplastic agent in the last 30 days? Examples of antineoplastic
    [Show full text]
  • European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa As a Treatment for Patients with Hypophosphatasia
    July 24, 2014 European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia -- Application designated for review under accelerated assessment process -- CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Marketing Authorization Application (MAA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia (HPP), has been validated and granted accelerated assessment by the European Medicines Agency (EMA). The acceptance of this MAA marks the beginning of the review process in the European Union (EU) for this potential new treatment. "HPP is a devastating disease for patients and their families due to progressive deterioration of bones and muscle weakness, which can result in impaired respiratory function, severe disability and death," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "If approved, asfotase alfa would be the first therapy for patients with this life-threatening disorder." The EU filing includes positive data from 68 patients with pediatric-onset HPP (ranging from newborns to 66 years of age) enrolled in three pivotal prospective studies and their extensions, as well as a retrospective natural history study in infants. In April, Alexion initiated the rolling submission of a Biologics License Application (BLA) for asfotase alfa as a treatment for patients with HPP with the U.S. Food and Drug Administration (FDA). About
    [Show full text]
  • Keeping up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A
    Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A. Shlom, PharmD, BCPS Senior Vice President & Director Clinical Pharmacy Program | Acurity, Inc. Privileged and Confidential April 10, 2019 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ▪ Identify orphan drugs and first-in-class medications approved by the FDA in 2018. ▪ List five new drugs and their indications. ▪ Identify the place in therapy for three novel monoclonal antibodies. ▪ Discuss at least two new medications that address public health concerns. Dr. Shlom does not have any conflicts of interest in regard to this presentation. Both trade names and generic names will be discussed throughout the presentation Privileged and Confidential 2018 NDA Approvals (NMEs/BLAs) ▪ Lutathera (lutetium Lu 177 dotatate) ▪ Braftovi (encorafenib) ▪ Vizimpro (dacomitinib) ▪ Biktarvy (bictegravir, emtricitabine, ▪ TPOXX (tecovirimat) ▪ Libtayo (cemiplimab-rwic) tenofovir, ▪ Tibsovo (ivosidenib) ▪ Seysara (sarecycline) alafenamide) ▪ Krintafel (tafenoquine) ▪ Nuzyra (omadacycline) ▪ Symdeko (tezacaftor, ivacaftor) ▪ Orilissa (elagolix sodium) ▪ Revcovi (elapegademase-lvir) ▪ Erleada (apalutamide) ▪ Omegaven (fish oil triglycerides) ▪ Tegsedi (inotersen) ▪ Trogarzo (ibalizumab-uiyk) ▪ Mulpleta (lusutrombopag) ▪ Talzenna (talazoparib) ▪ Ilumya (tildrakizumab-asmn) ▪ Poteligeo (mogamulizumab-kpkc) ▪ Xofluza (baloxavir marboxil) ▪ Tavalisse (fostamatinib disodium) ▪ Onpattro (patisiran)
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • Myelodysplastic Syndromes
    MYELODYSPLASTIC SYNDROMES TREATMENT REGIMENS (Part 1 of 3) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. First-Line Treatment1 Note: All recommendations are Category 2A unless otherwise indicated. Relatively Lower-Risk Patientsa,b Symptomatic Anemia With del(5q) ± One Other Cytogenetic Abnormality (except those involving chromosome 7) REGIMEN DOSING Lenalidomide2-5,c Days 1–21: Lenalidomide 10mg orally once daily. Repeat cycle every 28 days (or 28 days monthly). Assess response 2–4 months after initiation of treatment.
    [Show full text]
  • Asfotase Alfa for Infants and Young Children with Hypophosphatasia: 7 Year Outcomes of a Single-Arm, Open-Label, Phase 2 Extension Trial
    Articles Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial Michael P Whyte, Jill H Simmons, Scott Moseley, Kenji P Fujita, Nicholas Bishop, Nada J Salman, John Taylor, Dawn Phillips, Mairead McGinn, William H McAlister Summary Background Our previous phase 2, open-label study of 11 infants and young children with life-threatening perinatal or Lancet Diabetes Endocrinol infantile hypophosphatasia showed 1 year safety and efficacy of asfotase alfa, an enzyme replacement therapy. We 2019; 7: 93–105 aimed to report the long-term outcomes over approximately 7 years of treatment. Published Online December 14, 2018 http://dx.doi.org/10.1016/ Methods We did a prespecified, end of study, 7 year follow-up of our single-arm, open-label, phase 2 trial in which S2213-8587(18)30307-3 children aged 3 years or younger with life-threatening perinatal or infantile hypophosphatasia were recruited from This online publication has been ten hospitals (six in the USA, two in the UK, one in Canada, and one in the United Arab Emirates). Patients received corrected. The corrected version asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week if required) for first appeared at thelancet. up to 7 years (primary treatment period plus extension phase) or until the product became commercially available; com/diabetes-endocrinology on January 22, 2019 dosage adjustments were made at each visit according to changes in the patient’s weight. The primary objectives of See Comment page 76 this extension study were to assess the long-term tolerability of asfotase alfa, defined as the number of patients with Center for Metabolic Bone one or more treatment-emergent adverse events, and skeletal manifestations associated with hypophosphatasia, Disease and Molecular evaluated using the Radiographic Global Impression of Change (RGI-C) scale (−3 indicating severe worsening, and Research, Shriners Hospital for +3 complete or near-complete healing).
    [Show full text]
  • Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13
    MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14 CHANGES TO VERSION 13 PUBLISHED APRIL 2019 Changes to v13 Lines removed SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER ADULT TA'S (TA195, TA373, ABATACEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE √ MEDICINES FOR CHILDREN TA375) POLICY) Now covered by comment 8 PAEDIATRIC INDICATIONS (IN AS PER TA455 OR ADULT TA'S (TA130 LINE WITH NHS ENGLAND (replaced by TA375), TA143 (repalced by ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ MEDICINES FOR CHILDREN TA383), TA146, TA187, TA199, TA329, POLICY) TA392, TA460) Now covered by comment 8 ALBUTREPENONACOG ALFA HAEMOPHILIA B PRODUCTS ON CMU Blood factor products simplified NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 √ FRAMEWORK to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 AS PER BCSH GUIDELINES ANTIHAEMOPHILIC FACTOR/VON
    [Show full text]
  • UWHC Guidelines for the Use of Darbepoetin and Epoetin
    Use of Darbepoetin and Epoetin in Non-Nephrology Patients – Adult/Pediatric – Inpatient/Ambulatory Clinical Practice Guideline Table of Contents Executive Summary ......................................................................................... 3 Scope ............................................................................................................. 7 Methodology ................................................................................................... 7 Definitions (optional): ...................................................................................... 8 Introduction.................................................................................................... 8 Recommendations........................................................................................... 9 UW Health Implementation............................................................................ 19 References ................................................................................................... 19 Note: Active Table of Contents Click to follow link CPG Contact for Changes: Name: Philip Trapskin, PharmD, BCPS, Manager, DPP Phone Number: 608-263-1328 Email address: [email protected] CPG Contact for Content: Name: Jason Bergsbaken, PharmD Phone Number: 608-265-0341 Email address: [email protected] Copyright © 2015 University of Wisconsin Hospitals and Clinics Authority Contact: [email protected] Vermeulen, [email protected] Last Revised: 07/2015 Guideline Authors: Jason Bergsbaken, PharmD Coordinating
    [Show full text]
  • Asfotase Alfa (Strensiq) for Treatment of Hypophosphatasia in Infants and Children
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 08: Functional Limitations and Disability Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process.
    [Show full text]
  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
    Transaction Drug 1st (DIN) 2nd (PIN) 3rd (PIN) 4th (PIN) 5th (PIN) 6th (PIN) 7th (PIN) 8th (PIN) 9th (PIN) 10th (PIN) 11th (PIN) 12th (PIN) 13th (PIN) Alectinib (Alecensaro®) 02458136 00904400 − − − − − − − − − − − 150 mg capsule Alemtuzumab (LemtradaTM) 02418320 00904161 00904162 00904163 00904164 00904165 00904166 00904167 − − − − − 12 mg / 1.2 mL single-use vial Asfotase alfa (Strensiq®) 02444615 00904483 00904484 00904485 − − − − − − − − − 18 mg / 0.45 mL single-use vial Asfotase alfa (Strensiq®) 02444623 00904486 00904487 00904488 00904489 00904490 − − − − − − − 28 mg / 0.7 mL single-use vial Asfotase alfa (Strensiq®) 02444631 00904491 00904492 00904493 − − − − − − − − − 40 mg / 1 mL single-use vial Asfotase alfa (Strensiq®) 02444658 00904494 00904495 00904496 00904497 00904498 00904499 00904500 00904501 00904502 00904504 00904505 − 80 mg / 0.8 mL single-use vial Canakinumab (Ilaris®) 150 mg/mL powder for solution 02344939 00904404 00903809 00904410 − − − − − − − − − for injection Canakinumab (Ilaris®) 02460351 00904405 00904411 00904412 − − − − − − − − − 150 mg/mL solution for injection Ceftolozane / Tazobactam 02446901 00904433 − − − − − − − − − − − (Zerbaxa®) 1 g / 0.5 g vial Cerliponase Alfa (Brineura®) 150 mg / 5 mL solution for 02484013 00904634 00904635 00904636 − − − − − − − − − intracerebroventricular infusion Cladribine (MavencladTM) 02470179 00904524 00904525 00904526 00904642 − − − − − − − − 10 mg tablet Cysteamine (ProcysbiTM) 02464713 00904354 00904355 − − − − − − − − − − 75 mg delayed-release capsule Daclastavir (DaklinzaTM)
    [Show full text]